Apollon Wealth Management LLC Takes Position in Omnicell, Inc. (NASDAQ:OMCL)

Apollon Wealth Management LLC bought a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 5,718 shares of the company’s stock, valued at approximately $249,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of OMCL. Nisa Investment Advisors LLC lifted its stake in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the last quarter. EntryPoint Capital LLC boosted its holdings in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares during the period. CWM LLC increased its stake in Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares during the period. Finally, 1620 Investment Advisors Inc. lifted its position in shares of Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on OMCL. Benchmark reaffirmed a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Wells Fargo & Company increased their price objective on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Bank of America reiterated a “neutral” rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. JPMorgan Chase & Co. lifted their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Finally, Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $50.83.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $46.05 on Tuesday. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74. The business has a fifty day moving average price of $44.20 and a 200 day moving average price of $36.96. The stock has a market capitalization of $2.13 billion, a P/E ratio of -118.07, a price-to-earnings-growth ratio of 43.97 and a beta of 0.81.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.